Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal International Journal of Integrated Health Sciences Indian Journal of Forensic Medicine & Toxicology
Zahrah Hikmah, Zahrah
Allergy Immunology Division, Department Of Child Health, Faculty Of Medicine, Airlangga University-Dr. Soetomo General Hospital
Health Professions Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Use of Superoxide Dismutase in Accelerating Symptom Relief in Asthmatic and House Dust Mite Allergic Children Receiving House Dust Mite Immunotherapy: Double Blind Randomized Controlled Clinical Trial Endaryanto, Anang; Hikmah, Zahrah; Harsono, Ariyanto
International Journal of Integrated Health Sciences Vol 3, No 2 (2015)
Publisher : International Journal of Integrated Health Sciences

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (3133.931 KB)

Abstract

Objective: To evaluate the efficacy of superoxide dismutase (SOD) in lung function (FEV1 reversibility) and respiratory symptoms (drug scores, symptoms scores) in asthmatic and house dust mite allergic children receiving house dust mites immunotherapy.Methods: Forty subjects aged 6–17 years old with asthma and tested positive for house dust mite allergy on skin prick test, and received immunotherapy were enrolled in this study. All subjects completed clinical based assessments and diary-based assessments for drug and symptom scores. Following a four-week baseline assessment, all subjects were randomized to receive SOD or placebo. Respiratory symptoms (drug and symptoms score) and FEV1 were evaluated at the end of the 1st, 2nd, 3rd, and 4th weeks after randomization. Drug score, symptoms score and FEV1 reversibility test results were analyzed using a Paired t test and repeated measure of ANOVA. Results: There was a significant difference in drug scores, symptoms score and FEV1 reversibility test outcomes between SOD and placebo. SOD group showed a significant decrease in all outcome measures compared to those in placebo group. Conclusions: The use of SOD as antioxidants is effective in accelerating symptom relief for children with asthma and house dust mite allergy receiving house dust mite immunotherapy. Keywords: Allergic asthma, antioxidant, drug score, immunotherapy, symptoms score DOI: 10.15850/ijihs.v3n2.587
Immunotherapy Duration and Risk of Psychosocial Emotion and Risk of Attention Deficit Hyperactivity Disorder Prevalence and Relation in Allergic Rhinitis Children Dinda Anes Tunjungsari; Anang Endaryanto; Ahmad Suryawan; Ariyanto Harsono; Zahrah Hikmah; Azwin Mengindra Putera
Indian Journal of Forensic Medicine & Toxicology Vol. 15 No. 2 (2021): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v15i2.14707

Abstract

Background: Allergic rhinitis (AR) is the most common chronic disease in children. Allergic symptomsaffect daily activities and increase risk of psychosocial emotion and attention deficit hyperactivity disorder(ADHD). Immunotherapy has been proven in improving AR symptomsObjective: To identify prevalence of the risk of psychosocial emotion disorder and ADHD and its relationwith immunotherapy duration in AR children.Methods: A cross-sectional study was held in AR children aged 4-18 years at Allergy Immunology OutpatientClinic, Dr. Soetomo Hospital, during March 2017. Immunotherapy duration categorized into 0-6 months, 6months-1 year, 1-2 years, 2-3 years. Psychosocial emotion disorder risk assessed using Pediatric SymptomsChecklist 17 (PSC-17), scored into four different subscales: Internalizing, Externalizing, Attention, andTotal Score. ADHD risk was assessed using Abbreviated Conner’s Rating Scale (ACRS). Statistical analysisusing One-Way ANOVA and Eta test, with a value of p< 0.05 considered as significant.Results: Total of 37 children included. Based on immunotherapy duration 0-6 months, 6 months-1 year, 1-2years, and 2-3 years, prevalence risk of ADHD are 20.6%, 15.4%, 12.5%, and 12.5%, and prevalence ofpsychosocial emotion disorder risk are only in immunotherapy duration 6 months-1 year 12.5%. There wereno correlation between immunotherapy duration with risk of psychosocial emotion disorder (p = 0.945) andsignificantly correlated to ADHD (p = 0.049, r = 0.326).Conclusion: Prevalence risk of ADHD decrease as the immunotherapy duration increase and immunotherapyduration weakly correlated with risk of ADHD.
Co-Authors Ahmad Suryawan Anang Endaryanto Ariyanto Harsono Ariyanto Harsono, Ariyanto Azwin Mengindra Putera Dinda Anes Tunjungsari